CCM
RANI icon

Crossvault Capital Management’s Rani Therapeutics RANI Stock Holding History

Crossvault Capital Management’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$148K Buy
+14,285
New +$164K 0.06% 74

Other funds holding RANI

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ASGS
Alpha Square Group S New York $103M AUM 63.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TWA
TPB Wealth Advisors San Antonio, Texas $183M AUM 9.21% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return

Crossvault Capital Management's RANI Position: Q2 2022 in Review

Crossvault Capital Management opened a new position in Rani Therapeutics (RANI) in Q2 2022: 14,285 shares worth $148K. The stake represents 0.06% of the portfolio and ranks #74 among its holdings.

28 funds tracked by Wall St. Rank hold RANI as of Q2 2022.

  • Crossvault Capital Management held 14,285 shares of Rani Therapeutics worth $148K as of Q2 2022.
  • Rani Therapeutics was a new Crossvault Capital Management position in Q2 2022.
  • Rani Therapeutics made up 0.06% of Crossvault Capital Management's portfolio in Q2 2022, its #74 holding.
  • 28 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2022.

Based on Crossvault Capital Management's 13F filing for Q2 2022, filed 8 Aug 2022.